Azacitidine (5-AZA)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-04 — A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: Included in a Phase I/II JMML regimen combined with trametinib (with fludarabine + cytarabine added for high-risk disease), extending hypomethylating use into a pediatric MDS/MPN indication. (novelty: 3)
Open questions
Related
Contributing findings
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
09-sep-2026
novelty 2
per-area 1
mentions
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
04-sep-2026
novelty 3
per-area 2
mentions
Dose schedule modifications of 5-azacitidine monotherapy in myelodysplastic neoplasias and chronic myelomonocytic leukaemia.
19-jul-2026
novelty 2
per-area 2
strengthens
Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data-Linkage Study.
31-may-2026
novelty 2
per-area 2
mentions
🔎 Auto-added searches
| Query | Source | Added | Hits | Rationale |
|---|---|---|---|---|
("azacitidine"[Title/Abstract] OR "5-azacitidine"[Title/Abstract] OR "5-AZA"[Title/Abstract] OR Vidaza[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR CMML[Title/Abstract] OR "chronic myelomonocytic"[Title/Abstract] OR "MDS/MPN"[Title/Abstract] OR JMML[Title/Abstract]) |
pubmed | 20-sep-2026 | 1 / 12 | Targets azacitidine/5-AZA/Vidaza specifically (not the broader epigenetic/decitabine bundle already running) and adds CMML, JMML, and MDS/MPN overlap terms that match tagged findings and are missing from the existing azacitidine-containing query. |